See the DrugPatentWatch profile for Vyepti
Vyepti was approved by the U.S. Food and Drug Administration (FDA) on April 30, 2020 [1].
What is Vyepti and what does it treat?
Vyepti, also known by its generic name eptinezumab-a6YW, is an intravenous prescription medication used for the preventive treatment of migraine in adults [1]. It is a calcitonin gene-related peptide (CGRP) antagonist, designed to block the activity of CGRP, a molecule that plays a role in migraine pathophysiology [2].
How is Vyepti administered?
Vyepti is administered as an intravenous infusion every 12 weeks [1]. This administration method means it is given directly into a vein, typically in a clinical setting, over a period of time rather than as a pill or injection.
When does Vyepti's patent protection end?
Information regarding the specific patent expiry dates for Vyepti is not readily available in the provided context. DrugPatentWatch.com is a resource that tracks patent information for pharmaceutical products.
What are the side effects of Vyepti?
The most common side effects reported with Vyepti include upper respiratory tract infections and infusion-related reactions [1].
How does Vyepti compare to other migraine prevention treatments?
Vyepti belongs to a class of drugs known as CGRP inhibitors, which also includes other intravenous, subcutaneous, and oral medications [3]. While Vyepti is administered intravenously every 12 weeks, other CGRP inhibitors may have different dosing frequencies and administration routes, such as monthly injections or daily oral pills [3]. The choice of treatment often depends on individual patient needs, preferences, and physician recommendations.
What clinical trials supported Vyepti's approval?
Vyepti's approval was based on data from clinical trials, including two pivotal Phase 3 studies, PROMISE 1 and PROMISE 2 [1]. These trials evaluated the efficacy and safety of Vyepti in adults experiencing episodic and chronic migraines, respectively.
Who manufactures Vyepti?
Vyepti is manufactured by Lundbeck [4].
Are there any regulatory concerns or updates regarding Vyepti?
There are no specific regulatory concerns or updates mentioned in the provided information regarding Vyepti.
What are patient considerations for Vyepti?
Patients considering Vyepti should discuss its benefits and risks with their healthcare provider. This includes understanding the administration schedule, potential side effects like infusion reactions, and how it fits into their overall migraine management plan [1].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/vyepti-eptinezumab-a6yw
[2] https://www.drugpatentwatch.com/drugs/vyepti
[3] https://www.drugpatentwatch.com/blog/understanding-cgrp-inhibitors-for-migraine
[4] https://www.lundbeck.com/global/our-products/approved-products